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Globoid cell leukodystrophy (GLD), or Krabbe disease, is an inherited, neurologic disorder that results
from deficiency of a lysosomal enzyme, galactosylceramidase. Most commonly, deficits of galactosylcer-
amidase result in widespread central and peripheral nervous system demyelination and death in affected
infants typically by 2 years of age. Hematopoietic stem-cell transplantation is the current standard of
care in children diagnosed prior to symptom onset. However, disease correction is incomplete. Herein, the
first adeno-associated virus (AAV) gene therapy experiments are presented in a naturally occurring
canine model of GLD that closely recapitulates the clinical disease progression, neuropathological alter-
ations, and biochemical abnormalities observed in human patients. Adapted from studies in twitcher
mice, GLD dogs were treated by combination intravenous and intracerebroventricular injections of
AAVrh10 to target both the peripheral and central nervous systems. Combination of intravenous and
intracerebroventricular AAV gene therapy had a clear dose response and resulted in delayed onset of
clinical signs, extended life-span, correction of biochemical defects, and attenuation of neuropathology.
For the first time, therapeutic effect has been established in the canine model of GLD by targeting both
peripheral and central nervous system impairments with potential clinical implications for GLD patients.
Keywords: globoid cell leukodystrophy (Krabbe disease), canine model, AAV gene therapy, neurode-
generative disease, lysosomal storage disorder, leukodystrophy
INTRODUCTION
GLOBOID CELL LEUKODYSTROPHY (GLD), also known
asKrabbe disease, is a genetic, currently incurable,
neurodegenerative disease caused by a defect in
the gene encoding the hydrolytic enzyme galacto-
sylceramidase (GALC), which is responsible for
the lysosomal degradation of important myelin
lipids, including galactosylceramides. The defi-
ciency in GALC activity also results in the accu-
mulation of galactosylsphingosine (psychosine) to
levels that become toxic to oligodendrocytes and
Schwann cells, and causes diffuse central nervous
system (CNS) and peripheral nervous system
(PNS) demyelination. The prevalence of GLD in
families with European ancestry is estimated to be
about 1:100,000 live births in the United States.
Most individuals with GLD present as infants or in
early childhood with clinical signs of irritability,
stiffness, loss of developmental milestones, and
seizures, with disease progressing to the loss of
most bodily functions, a vegetative state, and early
childhood death.1,2
To date, the only available therapy for children
with GLD is hematopoietic stem-cell transplanta-
*Correspondence: Dr. Allison M. Bradbury, University of Pennsylvania, School of Veterinary Medicine, 3800 Spruce Street, 208 Rosenthal Building, Philadelphia, PA 19104.
E-mail: brada@upenn.edu















































tion (HSCT) from donor umbilical cord blood or
bone marrow. When infants are transplanted pre-
symptomatically, children initially show a slowing
of the disease progression.3 However, when fol-
lowed long term, 20%of transplanted children have
near normal function, 40% walk with assisted de-
vices, and the remaining 40% are severely im-
paired and wheelchair-bound.4 Continued disease
progression following HSCT is likely due to insuf-
ficient GALC activity in the CNS and/or insuffi-
cient treatment of the PNS.
Experimental therapies have been extensively
evaluated in the naturally occurring murine model
of GLD, the twitcher mouse. HSCT from enzy-
matically normal donor mice into twitcher mice
resulted in a moderate but significant increase in
life-span from about 40 days in untreated affected
mice to a mean of 80 days in transplanted mice.5–10
With the advent of safer and more efficient viral
vehicles, adeno-associated virus (AAV) gene ther-
apy has also been comprehensively evaluated in
twitcher mice over the last decade. Bilateral in-
tracerebroventricular (ICV) injections of AAV se-
rotype 1 encoding murine GALC (AAV1-mGALC)
into neonatal twitcher mice increased life-span to
a median of*56 days (66 days maximum).11 AAV
serotype 5 encoding murine GALC (AAV5-mGALC)
delivered by intracranial (IC) injection extended
life-span to an average of 63 days (66 days maxi-
mum),12 and IC plus intrathecal injection to a
median life-span of 71 days (78 days maximum).13
Intravenous (i.v.) delivery of AAV serotype rh10
encoding murine GALC (AAVrh10-mGALC) on
postnatal day 2 resulted in an average life-span of
55 days (63 days maximum), while mice treated
with ICV and intra-cerebellar injections lived an
average of 81 days (140 days maximum).14 Im-
portantly, combination of both i.v. and CNS-directed
gene therapy (ICV and intra-cerebellar) had a
synergistic effect and resulted in an average life-
span of 104 days, with several mice living up to
150 days. A second i.v. injection 5 days after the
initial dose further extended life-span to an aver-
age of 120 days.14 The dramatic improvements in
behavior, life-span, CNS GALC enzyme activity,
and CNS and PNS pathologywarranted evaluation
of combination i.v. and ICV AAV gene therapy in a
large-animal model of GLD.
GLD is a hereditary disease in dogs, and disease
progression closely recapitulates human disease.15–17
Dogs are the only naturally occurring diseasemodel
that results from a missense mutation, c.473A>C,
p.158Y>S, in the GALC gene, which is inherited as
an autosomal recessive trait.16 Transient trans-
fection of COS-1 cells with the mutant canine
GALC cDNA results in no GALC activity in
transfected cells,16 indicating that mutant protein
is not functional. Signs in affected dogs begin at*6
weeks of age with pelvic limb weakness, thoracic
limb dysmetria, and head tremor. Disease then
progresses to include ataxia, pelvic limb paresis,
urinary incontinence, and loss of hearing by 12
weeks of age. Pelvic limb paralysis warrants eu-
thanasia at a mean –SD of 15.7 –4.8 weeks of age
(n = 19).18 Magnetic resonance imaging (MRI) of
the brains of GLD dogs demonstrates changes
consistent with demyelination,19 and magnetic
resonance spectroscopy confirms decreases in
N-acetylaspartate and increases in choline, indic-
ative of neuronal loss and abnormal myelin turn-
over, respectively.20 Diffusion tensor imaging of
the canine GLD brain shows substantial decreases
in fractional anisotropy, increases in radial diffu-
sivity, and increases in apparent diffusion coeffi-
cient in the internal capsule, corona radiata, and
corpus callosum when compared to normal dogs.21
Consistent with imaging findings, histologic eval-
uation shows severe loss of myelin and globoid cell
accumulation in white matter.18 Brain biochemis-
try reveals decreased GALC activity and elevated
psychosine levels.15
Herein, the first AAV gene therapy experiments
in a large-animal model of GLD are presented.
Adapted from studies in twitcher mice,14 GLD-
affected dogs were treated by AAVrh10 vectors
encoding either a reporter protein or therapeutic
GALC transgene by combination i.v. and ICV in-
jections to evaluate the effect on both PNS andCNS
disease. For the first time, biodistribution studies
with a reporter protein delivered by combination
i.v. + ICV routes in a large animal are demon-
strated. More importantly, a therapeutic effect in
the canine model of GLD is also established, with
marked improvement seen in PNS function and
histology.
MATERIALS AND METHODS
Animals and AAV vector injections
Dogs were raised in the National Referral Cen-
ter for AnimalModels of HumanGenetic Disease of
the School of VeterinaryMedicine of theUniversity
of Pennsylvania (NIH OD P40-10939) under Na-
tional Institutes of Health and USDA guidelines
for the care and use of animals in research. The
experimental protocol was approved by the uni-
versity’s Institutional Animal Care and Use Com-
mittee. GLD in dogs is due to a missense mutation
GALC gene, c.473A>C, p.158Y>S. Whole blood
from dogs was tested for the GALC missense mu-















































tation using TaqMan real-time polymerase chain
reaction (PCR)-based DNA test to identify affected,
normal, and heterozygote dogs. The custom Taq-
Man SNP genotyping assay included forward
primer: ACTGGCCTTACGTGAATCTTCAG, and
reverse primer: GCTTGGCACCCACAATCC, with
VIC/NFQ as the reporter/quencher for allele 1 and
FAM/NFQ for allele 2. Using a TaqMan Geno-
typing Master Mix (#4371353, Life Technologies,
Grand Island, NY), the assay was run on an Ap-
plied Biosystems 7500 platform (Applied Biosys-
tems, Foster City, CA).
Two GLD dogs were treated with AAVrh10 ex-
pressing green florescent protein (GFP; AAVrh10-
GFP), one dog by i.v. injection alone and the second
dog by i.v. and ICV injection, at a dose of 4.3E12
vector genomes (vg; Table 1). All subsequent dogs
received i.v. and ICV injections. One GLD dog
was treated with AAVrh10 encoding the human
GALC transgene (AAVrh10-hGALC) at a total dose
of 3.5E12 vg (Table 1). Two GLD dogs received
AAVrh10-cGALC at a total dose of 1.2E12 vg (Ta-
ble 1; referred to as low dose), and two additional
GLD dogs were treated with an increased dose of
AAVrh10-cGALC, 3.8E13 vg (Table 1; referred to
as high dose). For i.v. injection of GLD dogs at
3 days of age, the skin was clipped and scrubbed
with 4% chlorohex followed by 70% isopropyl alco-
hol. A catheter was placed in the jugular vein.
Saline was injected to clear the line, then 500lL of
AAVrh10-GFP, 500lL of AAVrh10-hGALC, 500lL
of low-dose AAVrh10-cGALC, or 1,000lL of high-
dose AAVrh10-cGALC was injected over <1min, sa-
line was injected to clear the line, and the catheter
removed. For ICV injections at 6weeks of age, prior
to onset of neurological dysfunction, GLD dogs
were anesthetized with propofol, intubated, main-
tained on isoflurane, and placed in a Kopf stereo-
taxic head holder, and the head was clipped and
scrubbed for aseptic surgery. A 2-cm-long skin in-
cision was made in the dorsal midline of the skin
over the skull, and subcutaneous tissue was moved
aside. A 25G drill bit was used to drill a hole in the
left side of the skull at the following position: 0.5 cm
lateral and 1.0 cm caudal to the bregma. A 1.0mL
syringe with a 1.5† 22G needle was inserted into
the brain with 0.1mL of suction until cerebrospi-
nal fluid (CSF) was seen in the hub. The depth
was recorded, and the needle removed. A 1.0mL
syringe with a 1.5† 22G needle filled with 500lL
of AAVrh10-GFP, 1,000 lL of AAVrh10-hGALC,
500 lL of low-dose AAVrh10-cGALC, or 1,000 lL of
high-dose AAVrh10-cGALC was inserted into the
brain and advanced to the depth determined by the
first needle (*1–2 cm). Vector was injected into the
left lateral ventricle, and the needle was with-
drawn. A nylon skin suturewas placed, and the dog
was recovered. After all procedures, animals were
closely monitored. Untreated and treated GLD
dogs were euthanized at a humane endpoint de-
fined by complete pelvic limb paralysis. Eu-
thanasia was performed using an overdose of i.v.
barbiturate. After sacrifice, animals were perfused
through the left ventricle with 750mL of 0.9% cold
saline, and tissues were collected.
Vector production
GFP, human GALC, or canine GALC cDNA was
cloned into EcoRI site of a CB7 plasmid, down-
stream from the human CMV-enhancer/chicken
b-actin hybrid promoter. The accuracy of the
transgene was confirmed by sequencing, the in-
tegrity of the 5¢and 3¢ inverted terminal repeats
(ITRs) was confirmed by restriction enzyme anal-
ysis, and the functionality of the construct was
verified by in vitro cell transfection and measure-
ment of GALC enzyme activity. The plasmid was
cross-packaged by the Institute of Human Gene
Therapy at the University of Pennsylvania into
AAVrh10,22 and large-scale vector preparations
were generated, as previously described.23
Nerve conduction velocity
Dogs were anesthetized with propofol, endo-
tracheally intubated, andmaintained on isoflurane
anesthesia. Nerve conduction velocity (NCV) was
quantified using an electrodiagnostics machine
(Nicolet Viking Quest; Nicolet Biomedical, Madi-
son,WI).MotorNCV in the tibial, sciatic, and ulnar
nerves of the left limb was determined using
12mm, 29G subdermal needle recording electrodes
placed in the interosseous muscle. The tibial nerve
was electrically stimulated at the tarsus. The sci-
atic nerve was electrically stimulated at the stifle
and at the level of the femoral head. The ulnar
nerve was stimulated at the carpus and elbow.
Nerves were stimulated with monopolar stimulat-
ing electrodes placed subcutaneously for a duration
Table 1. Treatment cohorts and survival
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vg, vector genomes; i.v., intravenous; ICV, intracerebroventricular.















































of 200ls. Stimulus intensity was increased until a
M wave of maximal amplitude was obtained. Sen-
sory NCV was determined for the radial nerve.
Subcutaneous recording electrodes were placed
lateral to the radial nerve at the level of the elbow
and the skin over the dorsum of the paw and
stimulated with subcutaneous monopolar stimu-
lating electrodes for 200ls.
Brain-stem auditory evoked response
Dogs were anesthetized with propofol, endo-
tracheally intubated, and maintained on isoflurane
anesthesia. Brain-stem auditory evoked response
(BAER) data were recorded on a Nicolet Viking
Quest machine (Nicolet Biomedical) using 12mm,
29G subdermal needle recording electrodes. The
active electrode was placed in the skin over the os-
seous bulla of the stimulated ear, the reference
electrode in the skin over the vertex of the skull, and
the ground electrode in the skin over the contra-
lateral osseous bulla. Alternating rarefaction and
condensation clicks (0.1ms duration) were deliv-
ered to the stimulated ear at 11.1Hz using a 25 cm
plastic tube connected to a plastic ear piece placed
within the external ear canal. The filter settings for
the amplifier were set to 20Hz and 3kHz. One
thousand evoked responses were averaged for each
tracing obtained. Anamplifier sensitivity of 1lV/cm
was used to record the responses; the analysis time
was 10ms. Central conduction time was defined as
the time between the first and the fifth peak.
Hearing threshold was defined as the sound inten-
sity at which an evoked waveform was first visible.
Quantification of GALC enzyme activity
Tissue homogenates (20lg) in pure H2O were
incubated with fluorescent GALC substrate (6HMU-
beta-D-galactoside; Moscerdam Substrates, Oegst-
geest, TheNetherlands) for 17h at 37C.Enzymatic
activity was assessed via fluorescence, as measured
with a Beckmann Coulter DTX 880 multimode
detector using excitation/emission wavelengths of
385nm and 450nm, respectively.
Quantification of tissue psychosine
Psychosine from tissue homogenates (200lg)
was extracted via a methanol–acetic acid solution.
Analysiswas thenperformed onaShimadzu (Kyoto,
Japan) Nexera UHPLC system equipped with a
Waters Acquity UPLC BEH amide column and
coupled to a Shimadzu LCMS-8050 triple quadru-
pole mass spectrometer equipped with positive ion
electrospray. D-lactosyl-b1-1¢-D-erythro-sphingosine
(Avanti Polar Lipids, Alabaster, AL) was used as an
internal standard.
Quantification of CSF psychosine
Protein precipitation was performed to extract
psychosine from 50lL of dog CSF. Deuterated ga-
lactosyl sphingosine (psychosine d5: 1 ng/mL) was
used as an internal standard and was added to
the samples before extraction. Quality control (QC)
sampleswere prepared by pooling the extracts from
study samples. QC was run on every five-study
samples to make sure that the analytical method
and instrument response was constant. Sample
analysis was performed with a Shimadzu 20AD
HPLC system, coupled to a triple quadrupole mass
spectrometer (API 4000 QTrap; Sciex, Framing-
ham, MA) operated in MRMmode. The positive ion
ESI mode was used for detection of psychosine and
deuterated psychosine–d5. Data processing was
conducted with Analyst 1.5.1 (Applied Biosystems).
Vector quantification
Samples were stored at -80C until the time of
analysis. Total cellular DNA was extracted from
tissue using a QIAamp DNA Mini Kit (Qiagen,
Valencia, CA). Detection and quantification of vg
in extracted DNAwere performed by real-time PCR
(TaqMan Universal Master Mix; Applied Biosys-
tems) using a primer and FAM-TAMRA probe set
targeted to polyA adenylation signal in the vector.
The PCR conditions were: 100ng total cellular DNA
as template, 300nM primers, and 200nM probe per
reaction. Cycles were: 10min at 95C, 40 cycles of
15 s at 95C, and 1min at 60C. Results were com-
pared to a standard curve of known copy numbers
generated from the plasmid used to make vector.
Neutralizing antibody assay
Neutralizing antibody titers to AAVrh10 were
conducted at the Immunology Core in the Depart-
ment of Pathology and Laboratory Medicine at the
University of Pennsylvania. The assay was con-
ducted as previously described,24 with the excep-
tion of an initial dilution of 1:5 and use of HEK293
cell line.
Histology
Perfused brains were fixed in 4% paraformal-
dehyde, and paraffin embedded. Sections were cut
at 5l, and slides were deparaffinized and rehy-
drated in a series of xylenes and ethanols (100%,
95%, 70%). For myelin staining, slides were incu-
bated in an eriochrome cyanine R solution (#32752;
Sigma–Aldrich, St. Louis, MO) with ferric chloride
and sulfuric acid for 30min at room temperature,
rinsed in running water, and incubated in an iron
(III) nitrate nonahydrate (#216828; Sigma–Aldrich)
differentiating solution for 2–5min and rinsed in















































running water. Slides were counterstained with
eosin and dehydrated in a series of ethanols and
xylenes and mounted. For periodic acid–Schiff
(PAS) staining, slides were incubated in periodic
acid solution (#3951; Sigma–Aldrich) for 5min at
room temperature, rinsed with several changes of
water, followed by incubation in Schiff’s reagent
(#3952016; Sigma–Aldrich) for 15min. Slides were
rinsed in running water, dehydrated in a series of
ethanols and xylenes, and mounted. For immuno-
fluorescence, deparaffinized and rehydrated slides
were heated to a boil followed by a 30min incuba-
tion in antigen retrieval solution (#HK086; Biogenex,
Fremont, CA). Primary antibodies were diluted in
antibody diluent reagent solution (#003118; Life
Technologies, Waltham, MA) as follows: rabbit
polyclonal ionized calcium-binding adapter mole-
cule 1 (Iba1) (#CP290; Biocare, Concord, CA) 1:100;
mouse monoclonal glial fibrillary acidic protein
(GFAP; #556329; BD Pharmingen, San Jose, CA)
1:100; mouse monoclonal lysosomal-associated
membrane protein 1 (LAMP1; #B10407; LifeSpan
BioSciences, Seattle, WA) 1:750. They were then
incubated covered at 37C for 1h. Following three
5min washes with phosphate-buffered saline (PBS),
goat anti-mouse 488-conjugated (#A-11029; Ther-
mo Fisher Scientific, Waltham, MA) and goat anti-
rabbit 568-conjugated (#A-11036; Thermo Fisher
Scientific) secondary antibodies were applied at a
dilution of 1:500 in antibody diluent reagent solu-
tion. Following three 5min washes with PBS, slides
were stained with DAPI for 1min and mounted.
Peripheral nerve analysis: light microscopy
and morphometry
Peripheral nerve specimens were collected from
the sciatic, tibial, and superficial radial nerves
immediately following euthanasia and saline per-
fusion. Specimens were either immersion-fixed
into 10% neutral-buffered formalin or wrapped in a
saline dampened gauze sponge, placed into a wa-
tertight container, and chilled during transport.
Upon receipt, fixed nerveswere transferred to 2.5%
glutaraldehyde, post-fixed in 1% aqueous osmium
tetroxide, and processed to araldite resin blocks.
Sections (1 lm thick) were cut and stained with
toluidine blue and paraphenelenediamine prior to
light microscopic examination. Frozen sections of
each nerve were stained with modified Gomori
trichrome stain to localize myelin or reacted with
acid phosphatase to localize lipid-containing mac-
rophages (globoid cells).
For quantitative assessment, high-quality nerve
specimens adequately fixed and free of artifactwere
chosen. Using point counting techniques and a grid
with a magnified distance of 0.08mm between in-
tersection points, the fascicular area, defined as the
number of points falling on the endoneurium of
nerve fascicles, was determined. The total number
of myelinated fibers, the number of fibers with in-
appropriately thin myelin sheaths relative to their
axon diameter, as well as those with myelin split-
ting and ballooning, and the number of probable
regenerative clusters (defined as two or more clo-
sely apposed myelinated fibers) were assessed in
each nerve specimen and normalized to the fascic-
ular area. As previously described,25,26 only those
fibers with clear, faintly staining space evident
between separated myelin with an asymmetri-
cal profile were considered to have splitting and
ballooning, while profiles containing paranodal
regions or Schmidt–Lanterman clefts were not
counted. In addition, computer-assisted analyses of
axonal size–frequency distributions of myelinated
fibers, nerve fiber diameter, axonal diameter, my-
elin thickness, and G ratio (structural index of ax-
onal myelination defined as axonal diameter/fiber
diameter based on measurements by perimeter)
were determined using SPOT Advanced Imaging
software and modifications of Adobe Photoshop.
Statistics
Two-tailed, unpaired t-tests and figures were
conducted using Graph Pad Prism v6 (GraphPad
Software, La Jolla, CA). Levels of significance were
set at p-values of £0.05, £0.01, and £0.001.
RESULTS
Treatment cohorts and survival
Two GLD dogs received AAVrh10-GFP by either
i.v. injection alone or by a combination of i.v. and
ICV injections routes (Table 1). Intravenous injec-
tions were conducted at 3 days of age, once geno-
type was confirmed, and ICV injections were done
at 6 weeks of age, when dogs can safely undergo
general anesthesia and surgery. The two dogs were
euthanized at 11.3 and 17.4 weeks of age due to
signs of progressive GLD-related disease. This sur-
vival time is comparable to the mean life-span of
untreated GLD dogs (M –SD = 15.7 – 4.8 weeks;
n = 19).
Five GLD dogs received AAVrh10 encoding
the therapeutic GALC transgene by a combination
of i.v. and ICV routes at 3 days and 6 weeks of
age, respectively. One GLD dog was treated with
AAVrh10 encoding the human GALC transgene
(AAVrh10-hGALC) at a dose of 3.5E12 vg and died
at 9.1 weeks of age (Table 1). Due to the potential
for immunogenicity of the human transgene, the















































canine GALC cDNA was packaged into the same
AAVrh10 backbone (AAVrh10-cGALC). Two GLD
dogs received AAVrh10-cGALC at a dose of 1.2E12
vg (Table 1; referred to as low dose), divided evenly
between i.v. and ICV injection routes. These dogs
were euthanized at 17.9 and 22.1 weeks of age due
to signs of progressive GLD-related disease. Two
additional GLD dogs were treated with an increased
dose of AAVrh10-cGALC, 3.8E13 vg (Table 1; re-
ferred to as high dose), again divided evenly between
i.v. and ICV injection routes. Survival of high-dose-
treated dogs was increased to 30.3 and 43.1 weeks
of age, when the dogs were euthanized due to signs
of progressive GLD-related disease (Table 1).
Clinical evaluation of AAVrh10-treated dogs
Untreated GLD dogs show no neurological defi-
cits until approximately 6weeks of age. The earliest
signs of disease include tremors and ataxia. Se-
verity of tremors and ataxia increase over time, and
pelvic limbparalysis, the definedhumane endpoint,
develops by 15.7–4.8 weeks age18 (Supplementary
Video S1; untreated GLD dog at 14 weeks of age;
Supplementary Data are available online at www.
liebertpub.com/hum). Administration of AAVrh10-
GFP had no effect on the onset or progression of
clinical signs or life-span (SupplementaryVideo S1;
AAVrh10-GFP-treated dog at 15 weeks of age). In
contrast, a littermate GLD dog treated with low-
dose AAVrh10 encoding canine GALC had only
mild signs of neurologic disease at 15 weeks of age
(Supplementary Video S1; AAVrh10-cGALC low-
dose-treated dog at 15 weeks of age). Although both
GLD dogs that received low-dose AAVrh10-cGALC
showed improved ambulation at 15 weeks of age
compared to untreated dogs, both dogs were eu-
thanized due to pelvic limb paralysis at ages com-
parable to that of untreated GLD dogs.
In contrast, dogs that received high-dose AAVrh10-
cGALC showed a greater delay in the onset and
progression of clinical signs and lived longer. At
34 weeks of age, one dog treated with the high-
dose combination therapy had mild ataxia and
no evidence of tremor (Supplementary Video S2;
AAVrh10-cGALChigh-dose-treated dog at 34weeks
of age). This dog only became paralyzed at 43
weeks of age. The other dog from the high-dose
cohort progressed slightly more rapidly, as it
had moderate ataxia, resulting in repeated falling
when walking at 26 weeks of age, and became
paralyzed at 30 weeks of age. This dog also re-
mained without tremor at the defined endpoint.
Although progression was slowed in both dogs,
each dog eventually progressed to pelvic limb pa-
ralysis, the defined humane endpoint.
A single dog that was administered AAVrh10-
hGALC died suddenly at 9.1 weeks of age. At the
time of death, the dog showed tremor, pelvic limb
paresis, and spinal ataxia comparable to that of
untreated GLD dogs; pelvic limb paralysis was not
present. The cause of the sudden death was not
determined. However, clinical signs at the time of
death were consistent with near end-stage GLD
disease.
Peripheral NCV and BAER testing were per-
formed on untreated GLD dogs at the defined
endpoint (14–19 weeks of age; n =6), normal age-
matched control dogs (14–21 weeks; n = 9), and
AAVrh10-treated GLD dogs at the defined end-
point. Motor NCVs were significantly decreased
in untreated GLD dogs, indicative of demyelin-
ation, when compared to age-matched normal
control dogs for the tibial (Fig. 1A; p= 0.0093), sci-
atic (Fig. 1B; p= 0.0021), and ulnar nerves (Fig. 1C;
p= 0.0134). Sensory NCV of the superficial ra-
dial nerve was also significantly reduced (Fig. 1D;
p= 0.0033) in untreated GLD dogs when compared
to normal control dogs. As expected, i.v. and ICV
delivery of AAVrh10 encoding the reporter GFP
transgene had no effect on motor or sensory NCV.
AAVrh10 encoding canine GALC at a low dose had
amodest effect on NCVs (Fig. 1A–D). However, use
of high-dose AAVrh10-cGALC normalized NCV for
motor measurements (Fig. 1A–C) and nearly nor-
malized sensory NCV (Fig. 1D).
BAER testing demonstrated a significant in-
crease in central conduction time (data not shown)
and hearing threshold in the left (Supplementary
Fig. S1A; p= 0.0001) and right (Supplementary
Fig. S1B; p= 0.0015) ears of untreated GLD dogs
when compared to normal dogs. AAV-mediated
transfer of either transgene (GFP or canineGALC)
or dose (cGALC low or high) had a negligible ef-
fect, as treated animals showed no improvement in
central conduction time (data not shown) or hear-
ing threshold over untreated animals (Supple-
mentary Fig. S1A and B).
GALC and psychosine quantification
in AAVrh10-cGALC-treated GLD dogs
GALC activity and psychosine concentration
were measured in the cerebellum, cerebrum, lum-
bar spinal cord, sciatic nerve, and liver of normal,
GLD, and AAVrh10-cGALC-treated dogs (Table 2).
GALC activity was greatly reduced in the cere-
bellum of untreated GLD dogs to 0.04 pmol/h/lg
protein (SD =0.04; n =6), with many dogs below
the level of detection, when compared to normal
(0.31– 0.07 pmol/h/lg protein; n = 5). Correspond-
ingly, psychosine concentrations in this brain re-















































gion were increased 10-fold over normal, with an
average of 218.52 pmol/mg protein compared to
normal levels of 22.91pmol/mg protein (SD= 15.90;
n = 5). However, values were variable within the
untreated GLD cohort, with a range of 45.34–
748.39 (n =6). One GLD dog treated with high-dose
AAVrh10-cGALC achieved normal GALC activity
in the cerebellum (0.56 pmol/h/lg protein). How-
ever, cerebellar psychosine remained elevated at
159.47pmol/mg protein. The longer-living dog from
the high-dose cohort had supraphysiologic levels
of GALC in the cerebellum at 2.41 pmol/h/lg pro-
tein, and had psychosine concentrations within the
normal range (28.15 pmol/mg protein). GALC ac-
tivities in the cerebrum of normal (0.36 –0.10 pmol/
h/lg protein) and GLD (0.01 –0.00 pmol/h/lg pro-
tein) dogs were comparable to those found the
cerebellum. However, psychosine levels in the ce-
rebrum of normal (5.25 –3.94 pmol/mg protein) and
GLD (45.82–29.18 pmol/mg protein) dogs were
lower compared to the cerebellum. Both high-dose-
treated dogs had increased levels of GALC (0.23
and 0.22 pmol/h/lg protein) in the cerebrum com-
pared to untreated dogs, and the longer-living dog
again had a greater reduction of psychosine (21.92
compared to 41.93pmol/mg protein). In the lumbar
Figure 1. Nerve conduction velocity (NCV) in normal, globoid cell leukodystrophy (GLD), and adeno-associated virus (AAV)-treated dogs. NCV was conducted
on untreated GLD dogs at the defined humane endpoint (14–19 weeks of age; n = 6; solid square), normal age-matched control dogs (14–21 weeks; n= 9; solid
circle), and AAV-treated GLD dogs at endpoint (AAV-GFP, n = 1, solid diamond; AAVrh10-cGALC low dose, n= 2, solid triangle; AAVrh10-cGALC high dose, n= 2,
solid triangle). For pelvic limb motor NCV, the (A) tibial nerve was stimulated at the tarsus and stifle, the (B) sciatic nerve was stimulated at the stifle and at the
level of the femoral head, and for the thoracic limb the (C) ulnar nerve was stimulated at the carpus and elbow, and for sensory NCV the (D) radial nerve at the
level of the elbow. *p £ 0.05; **p £ 0.01.















































spinal cord, levels of psychosine in untreated GLD
dogs (307.05– 52.36pmol/mg protein compared to
normal 22.55– 4.03pmol/mg protein) were greater
than the cerebellum, despite slightly more GALC
activity (0.07– 0.03pmol/h/lg protein). Low-dose-
treated dogs had undetectable levels of GALC ac-
tivity in the lumbar cord. Yet, some reduction in
psychosine to 54.72 and 84.69pmol/mg protein was
achieved. High-dose-treated dogs had normalized
GALC levels (0.19 and 0.13 pmol/h/lg protein) and
variable reduction in psychosine concentration
(5.51 and 69.71 pmol/mg protein) in the lumbar
cord. In the sciatic nerve, GLD dogs had GALC
activity comparable to the brain 0.01 pmol/h/lg
protein (SD = 0.002), and the highest psychosine
levels in all regions tested, averaging 355.45pmol/
mg protein (SD =10.69). Normal dogs had lower
GALC activity (0.05– 0.05 pmol/h/lg protein) and
psychosine (17.10– 10.73pmol/mg protein) in the
sciatic nerve than the brain. In the low-dose cohort,
dogs had undetectable levels of GALC in the sciatic
nerve and only modestly reduced psychosine con-
centrations to 238.16 and 202.29pmol/mg protein,
while the high-dose-treated dogs had normal or
supraphysiological GALC (0.07 and 0.48 pmol/h/lg
protein) and greater reductions in psychosine
(17.39 and 42.76pmol/mg protein). In the liver,
GALC activity in normal dogs averaged 0.88 pmol/
h/lg protein (SD= 0.20; n = 5), and psychosine was
undetectable in all samples. In untreated GLD
dogs, GALC activity was reduced to 0.06 pmol/h/lg
protein (SD =0.02; n = 6), withmany dogs below the
level of detection. Psychosine concentration in the
liver of GLD dogs was elevated to 3.4 pmol/mg
protein (SD = 1.5; n = 6) and was highest in the two
oldest dogs evaluated (both >5pmol/mg protein).
Dogs treated with low-dose AAVrh10-cGALC had
modestly elevated GALC activities of 0.14 and
0.20pmol/h/lg protein, and psychosine levels com-
parable to untreated GLD dogs at 3.7 and 2.7pmol/
mg protein. Dogs treated with high-dose AAVrh10-
cGALC had completely normalized levels of GALC
in the liver (0.82 and 0.93 pmol/h/lg protein) and
considerably reduced psychosine concentration to
0.28 and 0.27 pmol/mg protein (Table 2).
CSF psychosine quantification
Psychosine was quantified in endpoint CSF
samples of the four dogs treated with AAVrh10-
cGALC, as well as untreated GLD dogs at the
endpoint (n = 5) and normal age-matched controls
(n = 5; Fig. 2). It was previously shown that CSF
psychosine concentrations were significantly ele-
vated in GLD affected dogs (p =0.004) compared


































































































































































































































































































































































































































































































































































































































































































































psychosine was undetectable.18 GLD dogs treated
with low-dose AAV had CSF psychosine concentra-
tions (2.39–0.54ng/mL) similar to untreated GLD
dogs. However, GLD dogs treated with high-dose
AAV had CSF psychosine concentrations (0.62–
0.23ng/mL) lower thanuntreatedand low-doseAAV-
treatedGLDdogs, despite being substantially older.
AAV vector quantification
AAVrh10 vector copy numbers were quantified
in the cerebellum, cerebrum, lumbar spinal cord,
sciatic nerve, and liver by quantitative PCR with
primers specific to the polyA adenylation signal of
the vector. The high-dose AAVrh10-cGALC-treated
dogs had the greatest number of vector copies in the
liver (6.02E + 06, 2.65E + 06), spinal cord (2.52E +
06, 3.06E + 06), and cerebellum (1.51E + 05, 1.04E +
06) and slightly reduced numbers in the cerebrum
(4.06E + 05, 7.10E + 05) and sciatic nerve (4.32E +
05, 3.67E + 05; Table 2). In all tissues analyzed, the
low-dose AAVrh10-cGALC-treated dogs had a re-
duced number of vector copies compared to the
high-dose cohort (Table 2). Untreated normal dogs
were used as controls.
AAVrh10 neutralizing antibody titers
Serum samples from all AAV-treated dogs and
untreated controls were analyzed for the presence
of neutralizing antibodies (NAbs) against AAVrh10.
There was an absence of NAbs against AAVrh10
in untreated control dog serum samples at a limit
of detection of 1:5. After i.v. injection but prior to
ICV injection (around 45 days post i.v. injection),
high-dose-treated dogs were seropositive for anti-
AAVrh10 NAbs at a titer of 1:2,560 and 1:5,120.
Interestingly, after ICV injection (60 days post
i.v. injection), anti-AAVrh10 NAbs increased to
1:81,920 and 1:40,960. By 75 days post i.v. injec-
tion, NAbs for one of the high-dose-treated dogs
decreased to 1:20,480 and further declined to
1:10,240 by 120 days post i.v. injection, where titers
remained (assayed every 30 days) until the end-
point. For the other high-dose-treated dog, injec-
tion titers at 75 days post i.v. injection decreased to
1:10,240 and further declined to 1:5,120 by 90 days
post i.v. injection, where they remained until the
endpoint. At 90 days post i.v. injection, low-dose-
treated dogs had titers of 1:5,120 and 1:10,240,
respectively, and comparable titers were found in
AAVrh10-GFP-treated dogs. As for the single dog
treated with human GALC, anti-AAVrh10 NAbs
after i.v. injection were 1:5,120 and increased to
1:81,920 after addition of the ICV injection (60 days
post i.v. injection).
GFP biodistribution
Both dogs that received AAVrh10-GFP (Table 1)
had a modest number of GFP-positive cortical
neurons in the cerebrum (Fig. 3A and B) and GFP-
positive Purkinje cells in the cerebellum (Fig. 3C
and D) determined by cell size and morphology.
Within the spinal cord, the single dog that received
i.v. and ICV injection routes had a greater number
of GFP-positive cells in the gray matter compared
to the dog that received i.v. injection alone (Fig. 3E
and F). Similarly, i.v. + ICV resulted in increased
GFP expression in the dorsal root ganglion when
compared to i.v. alone (Fig. 3G and H).
Histopathological evaluation of CNS
In untreated GLD dogs, there was near com-
plete loss of myelination in the central cerebellar
white matter, while the distal white matter of the
folia retained some degree ofmyelin, as indicated by
iron eriochrome (ECR) stain (Fig. 4B) and compared
to a normal age-matched control dog (Fig. 4A). Ac-
cumulation of PAS-positive storage material, asso-
ciated with infiltration of glycosphingolipid-laden
macrophages, was seen in the cerebellar white
matter of untreated GLD dogs (Fig. 4E) and was
absent in normal age-matched control tissue
(Fig. 4D). High-dose i.v. + ICV treatment with
AAVrh10-cGALC resulted in near normal myeli-
Figure 2. Cerebrospinal fluid (CSF) psychosine concentration in normal,
GLD, and AAV-treated dogs. CSF psychosine concentrations determined by
high-performance liquid chromatography (HPLC) coupled-mass spectrom-
etry and presented as concentration (ng/mL) for GLD-affected dogs (solid
square; n = 5; Mage= 13.4 weeks, range 10.9–16.4 weeks) compared to
normal control dogs (solid circle; n = 5; Mage = 18.0 weeks, range 6.1–38.7
weeks) and AAVrh10-treated GLD dogs at endpoint (AAVrh10-cGALC low
dose, n= 2, solid triangle; AAVrh10-cGALC high dose, n= 2, solid triangle).
**p£ 0.01.















































nation (Fig. 4C) and reduction in storage product
(Fig. 4F) in the cerebellum. There was a notable
isolated area of white matter in the anterior lobe
of the cerebellum and ventral pons that lacked
myelination (Fig. 4C, arrows) and contained PAS-
positive storage material (Fig. 4F, arrows).
Untreated GLD dogs demonstrated widespread
microgliosis (indicated with increased Iba1 expres-
sion, red stain) and astrocytosis (indicated with
increased GFAP expression, green stain; Fig. 4H)
associated with areas of demyelination and accu-
mulation of storage product compared to nor-
mal (Fig. 4G). High-dose i.v. + ICV treatment with
AAVrh10-cGALC largely prevented the infiltration
of microglia and astrocytes (Fig. 4I; region of in-
terest [ROI] indicated by white box in Fig. 4C),
Figure 3. GFP Immunofluorescence in AAV-GFP-treated GLD dogs. GFP immunofluorescence staining in GLD dogs treated with AAVrh10 encoding GFP by
intravenous (i.v.) and intracerebroventricular (ICV) or i.v. injection alone. Staining is shown in the cerebral cortex, cerebellum, spinal cord, and dorsal root
ganglion for an i.v. + ICV-treated GLD dog (A, C, E, and G) and i.v. only treated dog (B, D, F, and H). Bars in the lower right corner of images A and B = 50 lm
and C–H= 100 lm.















































except in the isolated areas of white matter that
lacked myelination and contained PAS-positive
storage material (Fig. 4I inset; ROI indicated by
arrow in anterior lobe of cerebellum in Fig. 4C and
F). In the untreated GLD dog, activated microglia
(red) showed increased expression of LAMP1
(green), an indication of lysosomal expansion
(Fig. 4K). In normal dogs, LAMP1 staining was
mostly isolated within large neurons and not mi-
croglia (Fig. 4J). Gene therapy normalized LAMP1
expression (Fig. 4L; ROI indicated by white box in
Fig. 4C), except in the isolated areas of white
Figure 4. Histopathology in normal, GLD, and AAV-treated dogs. Iron eriochrome (ECR) stain specific for myelination shown in (A) normal, (B) GLD, and (C)
high-dose AAV-treated dog at the level of the cerebellum. Periodic acid–Schiff (PAS) staining for polysaccharide detection in (D) normal, (E) GLD, and (F)
high-dose AAV-treated dog. Iba1 (red) staining for microglia and GFAP (green) staining for astrocytes in (G) normal, (H) GLD, and (I) high-dose AAV-treated
dogs. Region of image indicated by white squares in corresponding images A–C. Inset for (I) indicated by white arrow in anterior lobe of cerebellum. Iba1 (red)
staining for microglia and LAMP1 (green) staining for lysosomal membranes in (J) normal, (K) GLD, and (L) high-dose AAV-treated dog. Region of image
indicated by white squares in corresponding images (A–C). Inset for L indicated by white arrow in anterior lobe of cerebellum.















































matter in the anterior lobe of the cerebellum and
ventral pons (Fig. 4L inset; ROI indicated by arrow
in anterior lobe of cerebellum in Fig. 4C and F).
In the cerebrum, i.v. + ICV treatment with
AAVrh10-cGALC failed to attenuate myelin loss
fully or prevent storage accumulation (Supple-
mentary Fig. S2). However, the high-dose cohort
showed some modest improvement in myelination
and storage over the low-dose cohort, especially in
the longer-living dog (last column). In the spinal
cord, i.v. + ICV treatment with AAVrh10-cGALC
specifically failed to treat the lateral and ventral
corticospinal tracts in the high-dose-treated dogs.
In contrast to the cerebrum, the first dog of the low-
dose cohort had the greatest level of correction in
the spinal cord, while the second dog had diffuse
loss of myelin and accumulation of storage in the
white matter (Supplementary Fig. S3).
When analyzed by routine hematoxylin and eo-
sin staining, the single dog treated with the human
GALC transgene lacked infiltration of immune
cells and necrosis, suggesting that there was not an
acute immune reaction to the human protein. Ad-
ditionally, the dog showed severe loss of myelina-
tion (ECR) and accumulation of storage material




Sections from the sciatic (mixed motor and sen-
sory), tibial (mixed motor and sensory), and su-
perficial radial (sensory) nerves from normal,
untreated GLD, and AAVrh10-treated GLD dogs
were evaluated. Compared to normal dogs, scat-
tered nerve fibers from GLD-affected dogs showed
inappropriately thin myelin sheaths for the axonal
diameters (Fig. 5, 2nd row). Numerous acid phos-
phatase reactive macrophages (globoid cells) were
apparent in GLD-affected dogs (Supplementary
Fig. S4B) but not in normal age-matched control
dogs (Supplementary Fig. S4A). Treatment with
AAV-GFP did not reverse the histological changes
(Fig. 5, 3rd row). In contrast, high-dose treatment
with AAVrh10-GALC resulted in histologically
improved myelin thickness (Fig. 5, 5th row) and
loss of acid phosphatase reactive globoid cells in the
frozen nerve sections (Supplementary Fig. S4C).
Axonal size frequency analysis was performed
on the sciatic, tibial, and superficial radial nerves
of treated GLD dogs, compared to normal and un-
treated nerves, and presented as a percentage of
fibers £5lm (small) and >5lm (large; Table 3). A
shift toward a majority of small myelinated fibers
(£5 lm)was apparent in the untreatedGLDnerves,
while in AAVrh10-GALC high-dose-treated GLD
dogs, the ratio of small (£5lm) and large (>5 lm)
fibers was normalized. For example, for the tibial
nerve, GLD dogs had 87.84% and 96.27% of fibers
£5 lm compared to normal dogs where only 57.92%
and 69.14% of fibers were £5lm. As expected, af-
ter combination gene therapy with AAVrh10-GFP,
the frequency of axon size distribution was not
improved (73.2% and 86.16% of fibers £5 lm).
However, after treatment with high-dose AAVrh10-
cGALC, the ratio of fiber size was normalized
(53.76% and 66.65% of fibers £5 lm). The myelin-
ated fiber density, thin myelin fiber density, and
percentage of thinly myelinated fibers did not
quantitatively differ among groups (Supplemen-
tary Table S1). Compared to untreated dogs, the
average myelin thickness (Supplementary Table S2)
showed a trend toward normal thickness in GLD
dogs treated with high-dose AAVrh10-GALC ther-
apy. This trend toward normal myelin thickness
was consistentwith the histological findings (Fig. 5).
DISCUSSION
Herein, the first AAV gene therapy experiments
are presented in a canine model of GLD that
closely recapitulates the clinical disease progres-
sion, neuropathological alterations, and biochemi-
cal abnormalities observed in human patients.
Adapted from studies in twitcher mice, GLD dogs
were treated by combination i.v. and ICV injections
of AAVrh10 to target both PNS and CNS. Combi-
nation of i.v. and ICV AAV gene therapy had a
clear dose response and resulted in delayed onset of
clinical signs, extended life-span, correction of bio-
chemical defects, and attenuation of neuropathology.
In mucopolysaccharidosis VII (MPSVII) dogs, it
was previously shown that the addition of CNS-
directed delivery of AAVrh10 by intrathecal injec-
tion increased the activity of the deficient enzyme,
GUSB, in the brain and spinal cordwhen compared
to i.v. injection alone.27 This study, using AAVrh10
encoding GFP, evaluated if CNS-directed delivery
of vector by ICV delivery via the lateral ventricle
increased GFP expression when compared to i.v.
injection alone. Both injection routes resulted in a
modest number of GFP-positive cortical neurons
and Purkinje cells. Notably, addition of ICV injec-
tion increased the number of GFP-positive cells in
the gray matter of the spinal cord as well as dorsal
root ganglion. Peripheral nerves from these ani-
mals were not available for immunohistochemis-
try, as they were preserved for electron microscopy
andmorphometry studies. Importantly, in contrast
to the MPSVII study in which dogs received dif-















































Figure 5. Peripheral nerve histopathology in normal, GLD, and AAV-treated dogs. Resin sections (1 lm) from the sciatic (mixed motor and sensory), tibial
(mixed motor and sensory), and superficial radial (sensory) nerves of normal dogs (row 1), GLD (row 2), and AAV-treated dogs (rows 3–5) were evaluated using
the paraphenelenediamine stain. Bars in lower-right corner of bottom-row images= 25 lm for all images.
Table 3. Axonal size frequency distribution
Sciatic nerve Tibial nerve Superficial radial nerve
% Fibers £5lm % Fibers >5lm % Fibers £5 lm % Fibers >5lm % Fibers £5lm % Fibers >5lm
Normal
46.6 53.40 57.92 42.08 55.17 44.83
78.97 21.03 69.14 30.86 55.56 44.44
GLD
55.87 44.13 87.84 12.16 76.17 23.83
80.37 19.63 96.27 3.73 92.50 7.50
AAV-GFP
38.7 61.30 73.2 26.80 45.38 54.62
64.48 35.52 86.16 13.84 70.06 29.94
AAV-cGALC low dose
44.9 55.10 53.98 46.02 45.95 54.05
57.52 42.48 64.11 35.89 35.67 64.33
AAV-cGALC high dose
48.72 51.28 53.76 46.24 45.45 54.55
60.3 39.70 66.56 33.44 56.73 43.27
Each row represents the percentage of fibers and sum to 100 for each of the three nerves: sciatic nerve, tibial nerve, and superficial radial nerve. Each
column represents an individual dog.
GFP, green fluorescent protein.















































ferent AAV serotypes (AAV9 and AAVrh10) for i.v.
and intrathecal injections,27 this study also proved
the feasibility of combination systemic and CNS-
directed delivery using the same AAV serotype.
It has previously been shown in studies eval-
uating AAV gene therapy in a canine model of
MPSIIIA and a feline model of Sandhoff disease
that the use of species-specific transgenes decreases
immunogenicity and increases long-term trans-
gene expression.28,29 One GLD dog was treated
with AAVrh10 expressing human GALC by i.v.
and ICV delivery, and the dog showed no clinical
benefit and died suddenly at 9 weeks of age. Post-
mortem evaluation showed no signs of acute in-
flammation of the brain, suggesting that there was
not a detrimental immune reaction to the human
protein. However, no therapeutic benefit was seen,
although the dose was approximately three times
greater than that in the low-dose AAVrh10-cGALC
group and approximately 10 times less than that
of the high-dose AAVrh10-cGALC group. The dog
showed severe loss of myelin and accumulation of
storage material comparable to untreated GLD
dogs. Due to the unexpected death, endpoint elec-
trodiagnostic testing was not conducted, and fro-
zen tissues were not available for GALC and
psychosine analysis to compare to the dogs detailed
herein.
Additionally, four GLD dogs were treated with
AAVrh10 expressing species-specific canineGALC.
Combination i.v. and ICV delivery of AAVrh10-
cGALChad a clear dose-dependent response. High-
dose (3.8E13 vg) treated dogs had a greater delay in
disease onset and lived longer when compared to
low-dose (1.2E12 vg) treated dogs.
Notably, the GLD dogs treated with high dose
i.v. and ICV AAVrh10-cGALC maintained normal
nerve conduction velocities at the disease endpoint,
signifying that correction of peripheral nerve dis-
ease after gene therapy was sufficient and also not
transient. Despite correction of NCV, all AAVrh10-
cGALC-treated dogs still developed pelvic limb
spastic paralysis, suggesting that treatment of the
CNS but not the PNS was the limitation of the
therapy. Furthermore, neither low- nor high-dose-
treated dogs showed improvement in central con-
duction time or hearing threshold, indicating that
the therapy failed to correct auditory system ab-
normalities. This study on four dogs demonstrates
that i.v. treatment at 3 days of age is capable of
correcting the debilitating PNS disease associated
with GLD, but ICV delivery at 6 weeks of age
failed to correct CNS disease fully. This is impor-
tant, since children affected with GLD who receive
HSCT prior to the onset of symptoms, the current
standard of care, show only transient improvement
in NCV.30
In corroboration with NCV findings, high-
dose-treated dogs showed improvement in mye-
lin thickness and loss of acid phosphatase reactive
globoid cells when compared to untreated and low-
dose-treated dogs. Both low- and high-dose-treated
dogs showed improvement in the ratio of small to
large axons compared to untreated GLD dogs. In-
sufficient animal numbers made morphometric
data difficult to interpret, as overlap in numer-
ous parameters was seen between normal and un-
treated GLD dogs. Analysis of additional control
animals is currently underway to define quantita-
tive changes more clearly in peripheral nerves of
GLD dogs.
In the CNS, high-dose-treated dogs showed
greater improvement in demyelination, reduction
in PAS-positive storage material, and attenuation
of neuroinflammation (indicated by Iba1 andGFAP
staining) and lysosomal accumulation (indicated
by LAMP1 staining). Interestingly, the cerebellum
showed greater improvement than did the cere-
brum in both low- and high-dose cohorts. It is hy-
pothesized that this could be due to the timing of
myelination in the normal dog brain, as myelina-
tion of the cerebellum occurs <4 weeks of age, while
myelination of the cerebrum is delayed until 4–16
weeks of age.31 The two dogs from the high-dose
cohort showed a similar pattern of spinal cord pa-
thology, with lack of myelin and corresponding
storage accumulation primarily limited to the lat-
eral and ventral corticospinal tracts. These find-
ings corroborate the pattern of correction in the
brain, as the corticospinal tract is the last to mye-
linate in the spinal cord. These deficiencies in the
cortical spinal tracts are consistent with the find-
ings of spastic paralysis and are similar to the
motor deficits present in children with GLD.
However, in the low-dose cohort, the longer-living
dog had near normal myelination and minimal
storage accumulation in the spinal cord, while the
shorter-living dog had widespread loss of myelin
and marked accumulation of storage throughout
the white matter and biochemically a higher con-
centration of psychosine.
Importantly, GLD dogs treated with the combi-
nation of i.v. and ICVAAV gene therapy still died of
GLD-related disease, which remained in the CNS.
Reasons for this include the possibilities that ICV
therapy was provided too late in the disease course;
too low a dose of AAVwas administered; and/or ICV
was an inefficient route of AAVadministration. The
authors have unpublished data demonstrating that
psychosine is significantly elevated in the CSF of















































GLD dogs by 4 weeks of age, suggesting that earlier
targeting of theCNSmay benecessary to treatGLD
effectively. The impact of psychosine has previously
been evaluated in rodent oligodendrocyte culture
and oligodendrocyte precursor-like cell lines, and
has been shown to impair differentiation and at
specific concentrations result in cell death.32,33 It is
plausible that by 6 weeks of age, impaired matu-
ration and/or death of oligodendrocytes in GLD
dogs subsequently reduced the cellular targets for
AAV-mediated GALC transduction, diminishing
therapeutic efficacy in the CNS.
The inability to normalize psychosine levels
despite complete restoration of GALC activity is
an important finding for optimizing therapeutic
outcomes. One plausible explanation is that psy-
chosine accumulation was present at the time of
treatment, and while further increase may have
been attenuated, it was not reversed. Accumulated
psychosine may also be located in non-lysosomal
compartments or membranes and not capable of
degradation by hydrolytic lysosomal GALC. It has
previously been demonstrated that psychosine ac-
cumulates in lipid rafts in the brain and sciatic
nerve of twitcher mice and in brain samples from
human GLD patients.34
In addition to the psychosine issues, the extent
of disease pathology in the brain of 6-week-oldGLD
dogs is unknown. If substantial disease pathology
is already present, this may limit the efficacy
of therapy provided at this point in time. Second,
only the high dose of AAVrh10 proved effective
in ameliorating CNS disease in the GLD dog. A
higher concentration may have proven to be in
more effective. Finally, there is some evidence
that intrathecal AAV administration results in
different patterns of gene expression, depending on
whether it is given ICV, at the cerebellmedullary
cistern, or lumbar cistern.35 Earlier treatment of
the CNS can be achieved by replacing ICV injec-
tions with less invasive cerebellomedullary cistern
injections, which are now being explored.
Biochemically, the high-dose-treated dogs achieved
normalized levels of GALC activity in the brain,
spinal cord, sciatic nerve, and liver. Not all tissues
were available for analysis for the low-dose cohort.
However, GALC activity was below the level of
detection in the spinal cord and sciatic nerve and
only modestly increased in the liver of low-dose-
treated dogs. The cerebellum and sciatic nerve
proved to have the highest level of psychosine ac-
cumulation in untreated GLD dogs. Notably, in the
cerebellum, one high-dose-treated dog had greater
than normal GALC activity. Yet, psychosine con-
centration was still seven times normal levels.
The longer-living high-dose-treated dog achieved
GALC activity in the cerebellum that was seven
times that found in normal dogs, with corre-
spondingly higher vector copies, and psychosine
concentration was reduced to near normal levels.
The longer-living high-dose-treated dog also had
lower psychosine levels in the cerebrum, spinal
cord, and liver. These results emphasize the im-
portance of not relying solely on restoration of
GALC enzyme activity as a therapeutic readout,
as psychosine concentration may serve as a more
functional indication of treatment efficacy.
It has been previously shown that psychosine is
significantly elevated in the CSF of untreated GLD
dogs compared to normal age-matched controls.18
Here, it has been demonstrated that high-dose-
treated dogs resulted in a greater reduction in
CSF psychosine levels when compared to low-dose-
treated and untreated GLD dogs, suggesting this
as a plausible biomarker of disease progression and
therapeutic efficacy. Psychosine levels after low-
dose AAV were higher than in untreated GLD
samples. This is believed to be due to the advanced
age of the low-dose-treated animals (21 and 18
weeks of age) compared to the untreatedGLDdogs,
which averaged 13.4 weeks of age. CSF samples for
this analysis were collected without the addition of
a detergent recently shown to reduce the loss of
lipid (data not shown). Therefore, it is expected
that values of CSF psychosine in all cohorts are
underrepresented here. Longitudinal analysis of
psychosine levels in serum, plasma, and CSF of
untreated GLD dogs is ongoing.
It is plausible that expression of the therapeutic
transgene from the ICV injection was compromised
by circulating Nabs to the AAVrh10 capsid and/or
GALC transgene due to prior exposure from the
systemic injection. After i.v. injection but prior to
ICV injection, high-dose-treated dogs were sero-
positive for anti-AAVrh10 NAbs at titers of 1:2,560
and 1:5,120. After ICV injection with the same
capsid, anti-AAVrh10 NAbs increased to 1:81,920
and 1:40,960. A large number of vector copies (>1E
+ 06) were present at the endpoint in the brain,
spinal cord, and liver, indicating that despite high
circulating antibody titers to the capsid, the hu-
moral immune response did not eliminate long-
term vector presence. Normal levels of GALC
activity were achieved in the brain, spinal cord,
sciatic nerve, and liver of high-dose-treated dogs,
which is not suggestive of a detrimental immune
response against the therapeutic protein. Due to
limited CSF volume from treated dogs, neutraliz-
ing antibodies were not assessed in the CSF. Pur-
ified canine GALC enzyme or peptide library were















































not available to serve as antigens to determine if an
immune response was present to the therapeutic
protein or if the i.v. dose was sufficient to tolerize
animals. In the aforementioned study, MPSVII
dogs received an i.v. injection at 3 days of age with
AAV9 or AAVrh10 followed by intrathecal injection
at 2months of age with the opposite serotype. Prior
i.v. delivery did not compromise distribution of the
intrathecal delivered vectorwhenadifferent serotype
wasused.27 This study demonstrates for thefirst time
feasibility of using the same vector capsid for both
systemic and CNS-directed injections in dogs.
The data provided above will be used to direct
future studies, including (1) evaluating the efficacy
of i.v. therapy alone on treating the PNS in GLD
dogs, and (2) studying how higher vector doses,
alternate CNS-directed injection routes, and ear-
lier intervention effect the treatment of CNS as-
pects of the disease. Finally, it was previously
demonstrated that AAVrh10 provides strong neu-
ronal transduction in the canine brain. However,
this serotype failed to transduce glia or oligoden-
drocytes.36 It is probable that targeting specific cell
types, namely oligodendrocytes, may also improve
disease outcome.
Most recently, HSCT in combination with AAV
gene therapy has been evaluated in the twitcher
mouse, and dramatic results were shown.37 These
studies are currently being adapted for the GLD
dog and are ongoing. HSCT was attempted in a
single GLD dog *20 years ago following whole-
body radiation, which confounded demyelination
pathology.19 In contrast, ongoing studies in twitcher
mice and GLD dogs utilize a clinically relevant
chemical ablation protocol. The effects of HSCT
alone and HSCT in combination with AAV gene
therapy will be compared to the GLD dogs treated
herein to help determine the best clinical course for
treatment of GLD.
CONCLUSION
For the first time, therapeutic effect in the
canine model of GLD has been established by
targeting both the PNS and CNS. Combination
i.v. and ICV AAV gene therapy had a clear dose-
dependent response, was capable of more than
doubling the life-span of GLD dogs, and largely
corrected PNS defects. These studies provide clear
direction in optimization of dose and CNS-directed
delivery, which are ongoing. It is believed that
strong preclinical data in this highly translatable
model will provide a direct route to clinical im-
plementation and improve the treatment outcomes
for children with GLD.
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